Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Reinnervate Enhances Commercial and Product Development Teams with Key Senior Appointments

Published: Wednesday, April 06, 2011
Last Updated: Wednesday, April 06, 2011
Bookmark and Share
Appointments of Richard Rowling as commercial director and Barry Lynch as marketing manager to lead the sales and marketing operations supporting alvetex®.

Reinnervate, has announced the appointments of Richard Rowling as Commercial Director and Barry Lynch as Marketing Manager to lead the sales and marketing operations supporting alvetex®, the Company’s breakthrough 3D cell culture technology. Dr Györgyi Talas also joins reinnervate as Product Development Manager.

The three new appointments represent an important milestone for reinnervate as it continues to expand its commercial and product development teams following the initial launch of alvetex® in a 12-well plate format late last year and in preparation for further product launches scheduled throughout 2011.

As Commercial Director, Richard Rowling will have overall responsibility for the sales and marketing strategy and brings to the position over 20 years of experience marketing life science products globally.

Since 2007, Richard worked as Sales and Marketing Director for Lab 901 Ltd where he was responsible for the commercialization of its new automated electrophoresis platform and for the development of a full marketing and sales plan for the company’s RNA and protein research products. Prior to Lab 901, Richard was the Director, European Marketing & Telesales at Invitrogen Ltd, a leading global life science supplier.

Barry Lynch’s career includes over 12 years of international sales and marketing experience. Most recently he worked as the International Business Manager at Oxford Immunotec Ltd where he led strategic and tactical market development activities including establishing a highly trained and effective network of distributors for the company’s tuberculosis infection diagnostic. Prior to that Barry spent over ten years in regional marketing and product management roles at Invitrogen and latterly Applied Biosystems (both now part of Life Technologies).

Dr Györgyi Talas joins reinnervate from Angel Biotechnology Plc where she was responsible for all process and product development activities in the area of cell culture and successfully facilitated their transition to GMP. She has over 20 years’ academic and industrial experience within the fields of tissue engineering and cell therapy. Györgyi also spent eight years as Senior Scientist and Project Leader at Intercytex Plc developing cell therapy products for woundcare and aesthetic medicine markets prior to the company’s sale in 2009.

Ashley Cooper, reinnervate’s CEO, said: “We are very pleased to have attracted commercial and product development professionals with the quality and experience of Richard, Barry and Györgyi. Reinnervate is entering a very exciting period following the launch of our first alvetex® product late last year. We had a tremendous reception to this launch and there appears to be great demand for alvetex® as researchers are increasingly moving towards 3D cell culture. With these excellent new appointments and a pipeline of innovative alvetex® products in development, reinnervate will now drive forward its commercial and product development strategies.”

Richard Rowling said, “Reinnervate has developed a truly unique technology in alvetex®, which has the potential to revolutionise 3D cell culture and provide better in vitro testing models. I am excited to be joining reinnervate at this crucial stage in its development and applying my experience to support its commercial ambitions.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reinnervate Partners with Oncotest and SBH Sciences
Companies to partner on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture.
Thursday, October 31, 2013
Reinnervate Ltd and Roslin Cellab Partner
Reinnervate Ltd announced that it is entering into a collaboration with Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.
Friday, September 20, 2013
3D cell Culture Firm Reinnervate and Specialist Oncology CRO Oncotest GmbH Enter Collaboration Agreement
Oncotest to offer enhanced pre-clinical oncology and cancer research screening services incorporating Alvetex®Scaffold 3D cell culture technology.
Monday, January 07, 2013
Reinnervate and Tecan Sign Co-marketing Agreement
Both Companies to develop automated 3D cell culture solutions for improved cellular assays.
Tuesday, November 27, 2012
Reinnervate and Roslin Cellab Announce Plans to Collaborate
Collaboration on the development of protocols for three dimensional growth of hESC’s using Alvetex®Scaffold.
Friday, April 27, 2012
Reinnervate and Kirkstall to Collaborate on New 3D Cell Culture Products
Companies will collaborate to bring next generation three dimensional (3D) cell culture products to market in 2012. The two UK companies develop cell culture systems that bridge the current gap between 2D in-vitro cell culture and animal models.
Monday, March 19, 2012
New Reinnervate Whitepaper Includes Details on Live 3D Cell Imaging in 3D Cell Culture Using Alvetex®
The release is set to help scientists make the switch from traditional 2D cell culture to 3D cell growth.
Monday, January 30, 2012
Reinnervate and Mirus Bio announce collaboration
Reinnervate and Mirus Bio announce commercial agreement to launch new range of products for the transfection of cells cultured in 3D.
Friday, November 18, 2011
Alvetex® Voted One of Most Technologically Significant New Research Products By R&D Magazine
Alvetex® enables genuine 3D cell growth to be performed routinely and cost effectively in cell biology laboratories.
Monday, June 27, 2011
Reinnervate Partners with AMS Biotechnology (Europe) Limited for Distribution of Alvetex®
Alvetex® is a unique and proprietary cell culture scaffold that enables genuine 3D cell growth to be performed routinely and cost-effectively in cell biology laboratories.
Wednesday, June 01, 2011
Alvetex® Named in the “Top Ten Life Science Innovations of 2010” by The Scientist Magazine
Reinnervate’s 3D cell culture technology selected as one the ten most exciting new tools to hit the life sciences market this year.
Monday, December 06, 2010
Reinnervate Partners with LGC for Global Distribution of Alvetex®
Additional collaboration to develop 3d cell cultures for applications in drug discovery and development.
Tuesday, November 30, 2010
Reinnervate Partners with LGC for Global Distribution of ALVETEX®
Additional collaboration to develop 3D cell cultures for applications in drug discovery and development.
Monday, November 29, 2010
Reinnervate Completes Expansion into New Purpose-Built Facility at Netpark
Reinnervate, a life sciences company driving the adoption of routine 3D cell culture, has announced its expansion into a new purpose-built research and production facility at NETPark near Sedgefield, UK.
Tuesday, November 16, 2010
Reinnervate Launches new Website with Interactive Technical Resource for Routine 3D Cell Culture
New site provides scientific and technical information on 3D cell culture based on Reinnervate’s core Alvetex® technology.
Wednesday, October 13, 2010
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos